瑞德西韦治疗新型冠状病毒肺炎——初步报告 - Suppr

Suppr

超能文献

Remdesivir for the Treatment of Covid-19 - Preliminary Report.

作者信息

Olalla Julián

机构信息

Hospital Costa del Sol, Marbella, Spain

出版信息

N Engl J Med. 2020 Sep 3;383(10):993-994. doi: 10.1056/NEJMc2022236. Epub 2020 Jul 10.

DOI:10.1056/NEJMc2022236

PMID:32649077

Abstract

摘要

相似文献

Remdesivir for the Treatment of Covid-19 - Preliminary Report.瑞德西韦治疗新型冠状病毒肺炎——初步报告

N Engl J Med. 2020 Sep 3;383(10):993-994. doi: 10.1056/NEJMc2022236. Epub 2020 Jul 10.

Remdesivir for the Treatment of Covid-19 - Preliminary Report.瑞德西韦治疗新型冠状病毒肺炎的初步报告

N Engl J Med. 2020 Sep 3;383(10):992-993. doi: 10.1056/NEJMc2022236. Epub 2020 Jul 10.

Remdesivir for the Treatment of Covid-19 - Preliminary Report.瑞德西韦治疗新型冠状病毒肺炎的初步报告

N Engl J Med. 2020 Sep 3;383(10):992. doi: 10.1056/NEJMc2022236. Epub 2020 Jul 10.

Remdesivir for the Treatment of Covid-19 - Preliminary Report.瑞德西韦治疗新型冠状病毒肺炎的初步报告。

N Engl J Med. 2020 Sep 3;383(10):993. doi: 10.1056/NEJMc2022236. Epub 2020 Jul 10.

Remdesivir for the Treatment of Covid-19 - Preliminary Report. Reply.瑞德西韦治疗新冠病毒病-初步报告。回复。

N Engl J Med. 2020 Sep 3;383(10):994. doi: 10.1056/NEJMc2022236. Epub 2020 Jul 10.

[Remdesivir for patients with COVID-19].[瑞德西韦用于新型冠状病毒肺炎患者]

Internist (Berl). 2020 Aug;61(8):869-872. doi: 10.1007/s00108-020-00836-7.

Arguments in favour of remdesivir for treating SARS-CoV-2 infections.支持瑞德西韦治疗新型冠状病毒感染的论据。

Int J Antimicrob Agents. 2020 Apr;55(4):105933. doi: 10.1016/j.ijantimicag.2020.105933. Epub 2020 Mar 6.

Efficacy of Remdesivir in COVID-19.瑞德西韦治疗新型冠状病毒肺炎的疗效

JAMA. 2020 Sep 15;324(11):1041-1042. doi: 10.1001/jama.2020.16337.

Pulmonary administration of remdesivir in the treatment of COVID-19.瑞德西韦肺部给药治疗新型冠状病毒肺炎

AAPS J. 2020 Sep 17;22(6):121. doi: 10.1208/s12248-020-00506-4.

Remdesivir and COVID-19.瑞德西韦与新型冠状病毒肺炎

Lancet. 2020 Oct 3;396(10256):953. doi: 10.1016/S0140-6736(20)32020-1.

引用本文的文献

Remdesivir for the treatment of COVID-19.瑞德西韦治疗 COVID-19。

Cochrane Database Syst Rev. 2023 Jan 25;1(1):CD014962. doi: 10.1002/14651858.CD014962.pub2.

The pandemic effect: The outlook of lung transplantation.大流行影响：肺移植的前景。

Respir Med Res. 2023 Jun;83:100967. doi: 10.1016/j.resmer.2022.100967. Epub 2022 Oct 18.

Bibliometric and visual analysis of cardiovascular diseases and COVID-19 research.心血管疾病与 COVID-19 研究的文献计量学和可视化分析。

Front Public Health. 2022 Dec 8;10:1022810. doi: 10.3389/fpubh.2022.1022810. eCollection 2022.

How COVID-19 Affects Lung Transplantation: A Comprehensive Review.新型冠状病毒肺炎如何影响肺移植：一项综合综述

J Clin Med. 2022 Jun 18;11(12):3513. doi: 10.3390/jcm11123513.

COVID-19 Risk Stratification and Mortality Prediction in Hospitalized Indian Patients: Harnessing clinical data for public health benefits.COVID-19 风险分层和住院印度患者的死亡率预测：利用临床数据造福公众健康。

PLoS One. 2022 Mar 17;17(3):e0264785. doi: 10.1371/journal.pone.0264785. eCollection 2022.

COVID-19 Drug Development.COVID-19 药物研发。

J Microbiol Biotechnol. 2022 Jan 28;32(1):1-5. doi: 10.4014/jmb.2110.10029.

Lung transplantation for coronavirus disease 2019 (COVID-19): The who, what, where, when, and why.2019冠状病毒病（COVID-19）的肺移植：何人、何事、何地、何时及为何。

J Thorac Cardiovasc Surg. 2022 Mar;163(3):865-868. doi: 10.1016/j.jtcvs.2021.06.061. Epub 2021 Jul 6.

Remdesivir for the treatment of COVID-19.瑞德西韦用于治疗新型冠状病毒肺炎。

Cochrane Database Syst Rev. 2021 Aug 5;8(8):CD014962. doi: 10.1002/14651858.CD014962.

Cost-effectiveness of Remdesivir and Dexamethasone for COVID-19 Treatment in South Africa.瑞德西韦和地塞米松用于南非COVID-19治疗的成本效益

Open Forum Infect Dis. 2021 Jan 29;8(3):ofab040. doi: 10.1093/ofid/ofab040. eCollection 2021 Mar.

Dissecting lipid metabolism alterations in SARS-CoV-2.解析 SARS-CoV-2 中的脂质代谢改变。

Prog Lipid Res. 2021 Apr;82:101092. doi: 10.1016/j.plipres.2021.101092. Epub 2021 Feb 8.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验